Key clinical trials of deucravacitinib (sponsored by Bristol Myers Squibb)

Drug(s)	Indication	Phase	Status	Location(s)	Identifier
Deucravacitinib, apremilast, placebo	Plaque psoriasis	III	Completed	Multinational	NCT03624127 (POETYK PSO-1)
Deucravacitinib, apremilast, placebo	Plaque psoriasis	III	Completed	Multinational	NCT03611751 (POETYK PSO-2)
Deucravacitinib, placebo	Plaque psoriasis	III	Completed	Multinational	NCT04167462 (POETYK PSO-3)
Deucravacitinib	Plaque psoriasis	III	Completed	Japan	NCT03924427 (POETYK PSO-4)
Deucravacitinib	Plaque psoriasis	III	Active, not recruiting	Multinational	NCT04036435 (POETYK PSO-LTE)
Deucravacitinib, placebo	Plaque psoriasis	III	Recruiting	Multinational	NCT04772079
Deucravacitinib, placebo	Psoriatic arthritis	III	Recruiting	Multinational	NCT04908202 (POETYK PsA-1)
Deucravacitinib, apremilast, placebo	Psoriatic arthritis	III	Recruiting	Multinational	NCT04908189 (POETYK PsA-2)
Deucravacitinib, placebo	Scalp psoriasis	IV	Not yet recruiting	Multinational	NCT05478499 (PSORIATYK SCALP)
Deucravacitinib	Plaque psoriasis	II	Completed	Multinational	NCT02931838
Deucravacitinib, ustekinumab, placebo	Psoriatic arthritis	II	Completed	Multinational	NCT03881059
Deucravacitinib, placebo	Systemic lupus erythematosus	II	Completed	Multinational	NCT03252587 (PAISLEY)
Deucravacitinib	Systemic lupus erythematosus	II	Active, not recruiting	Multinational	NCT03920267
Deucravacitinib, placebo	Ulcerative colitis	II	Active, not recruiting	Multinational	NCT03934216 (LATTICE-UC)
Deucravacitinib, placebo	Discoid lupus erythematosus, subacute cutaneous lupus erythematosus	II	Recruiting	Multinational	NCT04857034
Deucravacitinib, placebo	Crohn's disease	II	Recruiting	Multinational	NCT03599622 (LATTICE-CD)
Deucravacitinib	Crohn's disease, ulcerative colitis	II	Recruiting	Multinational	NCT04877990
Deucravacitinib, placebo	Ulcerative colitis	II	Recruiting	Multinational	NCT04613518